Analytical Data
-
基因名
CT45A3
- Application
-
别名
CT45A3; CT45-3; CT45-4; CT45A4Cancer/testis antigen family 45 member A3; Cancer/testis antigen 45-3; Cancer/testis antigen 45-4
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NHU0
-
表达区间
1-189aa
-
氨基酸序列
MTDKTEKVAVDPETVFKRPRECDSPSYQKRQRMALLARKQGAGDSLIAGSAMSKEKKLMTGHAIPPSQLDSQIDDFTGFSKDRMMQKPGSNAPVGGNVTSSFSGDDLECRETASSPKSQREINADIKRKLVKELRCVGQKYEKIFEMLEGVQGPTAVRKRFFESIIKEAARCMRRDFVKHLKKKLKRMI
-
分子量
47.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT45A3 is a cancer/testis (CT) antigen that has gained significant attention in the field of cancer immunology due to its restricted expression pattern and potential as a target for immunotherapy. CT antigens are normally expressed in the germ cells of the testes but are aberrantly activated in various malignancies, making them ideal candidates for cancer immunotherapy because they can elicit an immune response without affecting normal tissues. CT45A3, in particular, has been identified in several types of cancers, including melanoma and prostate cancer, where its expression correlates with tumor progression. Previous studies have highlighted its potential role in promoting cancer cell proliferation and survival, thus establishing CT45A3 as a novel biomarker for tumor detection. Researchers are investigating the mechanisms of CT45A3 expression in tumors, the immune responses it triggers, and its utility in diagnostic and therapeutic applications. Given the growing focus on personalized medicine, the elucidation of CT45A3's role in various cancers could lead to the development of targeted therapies and vaccines that harness the immune system to recognize and eliminate tumor cells, offering hope for improved treatment options for patients with cancer.
